Literature DB >> 23953221

Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein.

Audrey Courcoul1, Emmanuelle Vignot1, Roland Chapurlat2.   

Abstract

Erdheim-Chester disease is a rare non-langerhans systemic histiocytosis of unknown origin, associated with bone diseases and severe visceral complications. Therapies have been disappointing. A recombinant form of interleukin-1 receptor antagonist (anakinra) has been used in a few cases when usual treatment fails. We report a new case of successfully interleukin-1 receptor antagonist treatment in Erdheim-Chester disease.
Copyright © 2013 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Anakinra; Erdheim-Chester disease; Histiocytosis; Interleukin-1 receptor antagonist protein

Mesh：

Substances：

Year:  2013        PMID： 23953221     DOI： 10.1016/j.jbspin.2013.06.013

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


  9 in total

1.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease.

Authors:  Eli L Diamond; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Lynn Brody; Maria Arcila; Christian Bowers; Mark Fluchel
Journal:  Blood       Date:  2016-08-17       Impact factor: 22.113

Review 3.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 4.  Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Rheumatology (Oxford)       Date:  2015-07-23       Impact factor: 7.580

Review 5.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

6.  Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Authors:  Fréderic Franconieri; Samuel Deshayes; Hubert de Boysson; Salim Trad; Nicolas Martin Silva; Benjamin Terrier; Boris Bienvenu; Françoise Galateau-Sallé; Jean-François Emile; Alison C Johnson; Achille Aouba
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

Review 7.  Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease.

Authors:  Giulio Cavalli; Riccardo Biavasco; Bruno Borgiani; Lorenzo Dagna
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

8.  Potential neuroprotective effect of Anakinra in spinal cord injury in an in vivo experimental animal model.

Authors:  Askin E Hasturk; Erdal R Yilmaz; Erhan Turkoglu; Murat Arikan; Guray Togral; Nazli Hayirli; Berrin I Erguder; Oya Evirgen
Journal:  Neurosciences (Riyadh)       Date:  2015-04       Impact factor: 0.906

9.  Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.

Authors:  Alessandro Tomelleri; Giulio Cavalli; Giacomo De Luca; Corrado Campochiaro; Teresa D'Aliberti; Moreno Tresoldi; Lorenzo Dagna
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.